Survival Analysis of Nasopharyngeal Cancer Patients in Maharat Nakhon Ratchasima Hospital
Article Sidebar
Main Article Content
Abstract
Introduction: Nasopharyngeal cancer is the second common head and neck cancer. Main treatment was radiotherapy or combine radiotherapy and chemotherapy. Objectives: To analyse survival rate and prognostic factors of nasopharyngeal cancer patients in Maharat Nakhon Ratchasima Hospital. Patients & Methods: retrospective study from medical record of patients with histologically-proven nasopharyngeal cancer treated between January 2000 and December 2004 were eligible for this analytical study. Results: One hundred and thirty five Nasopharyngeal cancer patients were found. The majority of patients was Thai (99.3%) with an age range of 16-82 years (mean 51.4±13.4 years). The male: female ratio was 2.5:1. Nasopharyngeal cancer was classified as stage I (3.0%), stage II (6.0%), stage III (10.3%) and stage IV (80.7%). Distant metastasis was 10.4%, most common organs involved were bone and liver respectively. The overall 5-year survival rate was 30.7% (95% confidence interval = 21.5-40.4). Cumulative 5-year survival rate of patients in stage I,II,III and IV were 66.7, 87.5, 78.6 and 22.7% respectively. Older age, greater nodal size and distant metastasis were in dependent poor prognostic factors. Conclusion: Most of nasopharyngeal cancer patients in Maharat Nakhon Ratchasima Hospital came to see the otorhinolaryngologists at end stage of the disease. The overall 5-year survival rate was 30.7% (95% confidence interval=21.5-40.4). Older age, greater nodal size and distant metastasis were independent poor prognostic factors.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Deerasamee S, Martin N. Sontipong S. Vatanasapt V, Sriplung H. Sriampom S. et al. Cancer in Thailand. Vol II, 1992-1994: IARC Technical Report No.34: Lyon; 1999.p.34-5.
Giri PGS, Sarraf MA. Nasopharyngeal cancer. In:. Ensley JF. Gutkind JS, Jacobs JR, Lippman SM, editors. Head and neck cancer. Emerging perspective Calitornia Academie Press; 2003. p.491-505.
Ho JHC. An epidemiologic and clinical study of nasopha-ryngeal carcinoma. Int J Radiat Oncol Biol Phys 1978; 4: 183-94.
Sivanandan R. Willard EF, Jr. Malignant tumors of the nasopharynx. In: Cummings CW, editor. Otolaryngology Head & Neck Surgery. 4th ed. Pennsynvania Mo Mosby 2005.p.1672-81.
Kabfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiely & Sons; 1980.
Cox DR, Oakes D. Analysis of survival data. London: Chapman & Hall; 1984.
สถิติสาธารณสุข พ.ศ.2545 (Public Health Statistic 2002). สำนักนโยบายและยุทธศาสตร์ กระทรวงสาธาธารณสุข; 2545. หน้า 114-5.
เฉลิมชัย ชินตระการ, พวงทอง ไกรพิบูลย์, บุญซู กุลประ ดิษฐารมณ์, วิชัย อติชาตการ, ประพจน์ คล่องสู้ศึก, วรชัย รัตนธราธร และคณะ. มะเร็งหลังช่องจมูก ประสบการณ์ การรักษาและติดตามผลระยะเวลา 10 ปี. วารสารหู คอ จมูก และใบหน้า 2536; 1: 1-7.
พินิจ สัญฉนะวณิชย์, สุธี ไกรตระกูล, สมชาติ แสงสะอาด. อนุชา พัวไพโรจน์. มะเร็งหลังโพรงจมูก. วารสารหู คอ จมูก และใบหน้า 2531;; 2: 167-76.
ศเณศร์ แวววิจิตร. Nasopharyngeal carcinoma. วารสารหู คอ จมูก และใบหน้า 2530; 1:35-9.
Cooper JS, Scott C, Marcial V, Griffin T.FazekasJ, Laramore G, et al. The relationship of nasopharyngcal carcinomas and second independent malignancy based on the Radiotherapy Oncology Group experience. Cancer 1991;67:1673-7.
วุฒิพฤกย์ วิสุทธิ์. มะเร็งของโซฟาริงซ์ผลการรักมาด้วยรังสีโคบอลท์. วารสารโรคมะเร็ง 2520;3:59-67.
สุขถมยา จงดี , สุขถมยา วิมล. มะเร็งของเซฟาริงซ์. สารศิริราช2523;32:392-7.
Syed AMN, Puthawala AA, Damore SJ, Chaerlow JM, Austin PA, Sposto R. etal. Brachytherapy for primary and recurrent nasopharyngeal carcinoma: 20 year' experience in Long Beach Memorial. Int J Radiat Oncol Biol Phys 2000; 47: 1311-21.
Tate DJ, Adier JR, Chang SD, Marquez S, Eulau SM, Fee WE, et al. Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcimoma: Impact on local control. Int I Radiat Oncol Biol Phys19999; 45:915-21.
Lee AWM, Poon YF, Foo W. Retrospective analysis of 5,037 patients with nasopharyngeal carcinoma treated during 1976-1985; Overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 23: 261-70.
Sanguineti G, Geara FB, Garden AS.Carcinoma ofthe nasopharynx treated by radiotherapy alone: Determinant of local and regional control. Int I Radiat Oncol Biol Phys1997;37:985-96.
Hoppe RT, Goffinet DR, Bagshaw MA.Carcinoma of the masopharynx: Eighteen years' experience with megavoltage radiation therapy. Cancer 1976; 37: 2605-12.
นงพะงา สุวัฒนนันท์. Cancer education in Thailand. วารสารโรคมะเร็ง 2537;20:77-80.
Al-Sarraf M, LeBlanc M, Shanker PG Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase Ill randomized Intergroup Study 0099. J Clin Oncol 1998; 16: 1310-7.
International Nasopharynx Cancer Study Group: VUMCA I Trial. Prelinary results of a randomized trial comparing ncoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiothcrapy vs. radiotherapy alone in stage IV (>N2, MO) undifferentiated nasopharyngcal carcinoma: A positive effect on progression-free survival. Int I Radiat Oncol Biol Phys1996; 35:463-9.
Wang CC. improved local control of nasopharyngeal carcinoma after intracavitary brachytherapy boost. Am J Clin Oncol 1991; 14:5-8
Vikram B, Mishra S. Permanent Iodine-125 (I-125) boost implants after external radiation therapy in nasopharyngeal cancer. Int I Radiat Oncol Biol Phys 1994; 28: 699-701.
Daly JM, Hearne B. Dunaj LePorte B, Vikram b, Strong E, et al. Nutrition rehabilitation in patients with advanced head and neck cancer receiving radiation therapy. Am J Surg 1984; 148: 514-20.